Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestle sales

This article was originally published in The Tan Sheet

Executive Summary

"Robust innovation and renovation pipeline" for infant formula contributed to 6.6% growth in Nestle Nutrition sales to 5.7 bil. Swiss Francs ($4.87 bil.) for the January-September period, company announces Oct. 18. For the nine-month period, organic sales advanced 9.7%, "in line with the business' long-term target of 10%," firm adds. "NAN premium starter formulas and Nestle infant cereals enriched with probiotics to strengthen infants' immune systems, did particularly well in their global rollout," according to Nestle. Firm's Powdered and Liquid Beverages unit achieved sales of 12.8 bil. Swiss Francs ($10.9 bil.), representing growth of 7.5%, or 10% organically. Nestle also announces promotion of Acquisitions and Business Development Chief Jim Singh to CFO, and Paul Polman as head of Zone Americas, replacing Paul Bulcke, who will assume the CEO post in the spring (1"The Tan Sheet" Oct. 1, 2007, In Brief)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel